This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
and you are
over 12
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The objective of this study is to assess the efficacy and safety of different doses of Creon Immediate Release (IR) in comparison to Creon® 25,000 Delayed Release/Gastro-Resistant (DR/GR) in subjects with Pancreatic Exocrine Insufficiency (PEI) due to Cystis Fibrosis (CF).

Provided treatments

  • Drug: Creon IR
  • Drug: Creon® (DR/GR)
Tris trial is registered with FDA with number: NCT02415959. The sponsor of the trial is Abbott and it is looking for 70 volunteers for the current phase.
Official trial title:
A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis